#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Urea cycle disorder Epidermolysis bullosa Malignant neoplasm of choroid Acquired haemophilia Urethral valves Alexander disease Acute graft versus host disease Breast angiosarcoma Acute myeloid leukaemia refractory Follicular lymphoma stage II Gastrointestinal disorder Leukocyte adhesion deficiency type I Leukoencephalopathy Cholangitis sclerosing Chronic graft versus host disease in skin More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma recurrent – Life with Disease Cytokine release syndrome – Trials in Disease Epidermolysis bullosa – Diagnostics Hepatic angiosarcoma – Trials in Disease Glycogen storage disease type II – Life with Disease Synovial sarcoma – Basic Information Gastrointestinal stromal tumour – Treatment Alveolar rhabdomyosarcoma – Trials in Disease Progressive multifocal leukoencephalopathy – Basic Information Alternating hemiplegia of childhood – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metoprolol Gns561 Io103 Acetate Tobevibart Progesterone, Micronised Zidesamtinib Itepekimab 18F-Fludarabine Vibostolimab Galcanezumab CIRTUVIVINT Ibuprofen Meropenem Trihydrate [11C]Az14193391 Amphotericin B Theophylline Vilanterol Ifezuntirgene Inilparvovec Arachis Hypogaea Extract Fidanacogene Elaparvovec More therapies…

    Learn about Your Condition

    Intermittent claudication Cerebral haemorrhage Small intestine leiomyosarcoma Hereditary ataxia Pulmonary alveolar haemorrhage Right ventricular dysfunction Haemorrhagic stroke Juvenile absence epilepsy Juvenile spondyloarthritis Metastatic gastric cancer Amyloidosis Non-obstructive cardiomyopathy Acute myocardial infarction Myositis Meningioma malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer metastatic

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • RLY-2608
    • Capivasertib
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    • Datopotamab Deruxtecan
    France Italy Spain

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Exemestane
    • Everolimus
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    France

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Adenocarcinoma pancreas
    • Non-small cell lung cancer
    Investigated Drugs:
    • 177LU-FAP-2286
    • Calcium Folinate
    • Irinotecan
    Belgium France Italy Spain

  • Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Fluoroestradiol F-18
    • Elacestrant
    • Exemestane
    Italy
Previous Page
1 2 3 4 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!